Cargando…

Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?

Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2–3% of the general adult population worldwide. The interleukin (IL)-23/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new target...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellinato, Francesco, Chiricozzi, Andrea, Piaserico, Stefano, Targher, Giovanni, Gisondi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658165/
https://www.ncbi.nlm.nih.gov/pubmed/36361639
http://dx.doi.org/10.3390/ijms232112849
_version_ 1784829883025719296
author Bellinato, Francesco
Chiricozzi, Andrea
Piaserico, Stefano
Targher, Giovanni
Gisondi, Paolo
author_facet Bellinato, Francesco
Chiricozzi, Andrea
Piaserico, Stefano
Targher, Giovanni
Gisondi, Paolo
author_sort Bellinato, Francesco
collection PubMed
description Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2–3% of the general adult population worldwide. The interleukin (IL)-23/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new targeted pharmacotherapies. Cutaneous lesions tend to recur in the same body areas, likely because of the reactivation of tissue-resident memory T cells. The spillover of different pro-inflammatory cytokines into systemic circulation can promote the onset of different comorbidities, including psoriatic arthritis. New targeted pharmacotherapies may lead to almost complete skin clearance and significant improvements in the patient’s quality of life. Accumulating evidence supports the notion that early intervention with targeted pharmacotherapies could beneficially affect the clinical course of psoriatic disease at three different levels: (1) influencing the immune cells infiltrating the skin and gene expression, (2) the prevention of psoriasis-related comorbidities, especially psoriatic arthritis, and (3) the improvement of the patient’s quality of life and reduction of cumulative life course impairment. The main aim of this narrative review is to summarize the effects that new targeted pharmacotherapies for psoriasis may have on the immune scar, both at the molecular and cellular level, on psoriatic arthritis and on the patient’s quality of life.
format Online
Article
Text
id pubmed-9658165
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96581652022-11-15 Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis? Bellinato, Francesco Chiricozzi, Andrea Piaserico, Stefano Targher, Giovanni Gisondi, Paolo Int J Mol Sci Review Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2–3% of the general adult population worldwide. The interleukin (IL)-23/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new targeted pharmacotherapies. Cutaneous lesions tend to recur in the same body areas, likely because of the reactivation of tissue-resident memory T cells. The spillover of different pro-inflammatory cytokines into systemic circulation can promote the onset of different comorbidities, including psoriatic arthritis. New targeted pharmacotherapies may lead to almost complete skin clearance and significant improvements in the patient’s quality of life. Accumulating evidence supports the notion that early intervention with targeted pharmacotherapies could beneficially affect the clinical course of psoriatic disease at three different levels: (1) influencing the immune cells infiltrating the skin and gene expression, (2) the prevention of psoriasis-related comorbidities, especially psoriatic arthritis, and (3) the improvement of the patient’s quality of life and reduction of cumulative life course impairment. The main aim of this narrative review is to summarize the effects that new targeted pharmacotherapies for psoriasis may have on the immune scar, both at the molecular and cellular level, on psoriatic arthritis and on the patient’s quality of life. MDPI 2022-10-25 /pmc/articles/PMC9658165/ /pubmed/36361639 http://dx.doi.org/10.3390/ijms232112849 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bellinato, Francesco
Chiricozzi, Andrea
Piaserico, Stefano
Targher, Giovanni
Gisondi, Paolo
Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
title Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
title_full Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
title_fullStr Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
title_full_unstemmed Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
title_short Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
title_sort could targeted pharmacotherapies exert a “disease modification effect” in patients with chronic plaque psoriasis?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658165/
https://www.ncbi.nlm.nih.gov/pubmed/36361639
http://dx.doi.org/10.3390/ijms232112849
work_keys_str_mv AT bellinatofrancesco couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis
AT chiricozziandrea couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis
AT piasericostefano couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis
AT targhergiovanni couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis
AT gisondipaolo couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis